WI-ROCKWELL-AUTOMATION
Rockwell Automation, Inc. (NYSE: ROK), the world’s largest company dedicated to industrial automation and digital transformation, today announced the results of the 9th annual “State of Smart Manufacturing Report.” The global study surveyed more than 1,500 manufacturers across 17 of the leading manufacturing countries.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240326554889/en/
Rockwell Automation's 9th annual State of Smart Manufacturing Report (Graphic: Business Wire)
This year’s report reveals a focus on harnessing new and emerging technologies to build resiliency, improve quality, maximize workforce potential, and drive sustainable growth.
“A skilled workforce is the cornerstone of any successful manufacturing operation, but attracting, managing and retaining workers is proving to be an ongoing challenge,” said Cyril Perducat, senior vice president and chief technology officer, Rockwell Automation. “The survey found technology alone is not the answer. To remain competitive, manufacturers need to focus their staff on embracing new technology as a core part of their evolving organizational culture, creating a technology/worker partnership that drives their business forward.”
Key global findings include:
- AI ranks as the top capability that manufacturers believe will drive the biggest business outcomes. 83% of manufacturers expect to use generative AI (GenAI) in their operations in 2024.
- 95% of manufacturers are using or evaluating smart manufacturing technology – up from 84% in 2023.
- 94% of manufacturers plan to maintain or grow their workforce due to smart manufacturing technology adoption, with a heavy focus on repurposing workers to new or different roles and/or hiring more workers.
- Change management is the leading workforce-related obstacle for manufacturers in 2024.
- Manufacturers cite “improved quality” as the top positive outcome they hope to achieve from existing smart manufacturing technology for a second consecutive year. Additionally, “quality control” ranks as the #1 AI/Machine Learning use case in 2024.
- For the first time, cybersecurity is listed as one of the top five external risks for manufacturers in 2024, ranking third overall.
- Energy management is the factor that matters most to manufacturers’ sustainability/ESG programs.
“The workforce of 2019 is not coming back,” said Allison Kuhn, principal analyst, LNS Research. “Developing a sustainable workforce strategy is critical to successfully navigate daunting manufacturing challenges. Leaders are winning the war for talent by embracing this new reality and with a laser focus on three imperatives: 1) Total Employee Experience, 2) Servant Leadership, and 3) Connected Frontline Workforce (CFW) Applications.”
Manufacturers continue to face a significant challenge: combining people, processes, and technology to drive long-term business growth and resilience. According to the report, around one-third of manufacturing leaders cite “matching technology and talent to business need” and “effectively managing people and resources” as the biggest obstacles their organizations face over the next year. Manufacturers can overcome this challenge by selecting a partner with relevant industry expertise and experience who can provide tailored solutions and support in aligning technology and talent with business objectives.
“At Rockwell, the combination of our deep industry expertise with our exceptional PartnerNetwork™ puts us in the best position to advise and guide leading global manufacturers. Being the largest company dedicated solely to industrial automation and digital transformation, we strive to help companies realize the promise and value of their digital transformation, no matter where they are in their journey,” said Perducat.
The full findings of the report can be found here.
Methodology
This report analyzed feedback from 1,567 respondents from 17 of the top manufacturing countries with roles from management up to the C-suite and was conducted in association with Rockwell Automation and Sapio Research. The survey pulled from a range of industries including Consumer Packaged Goods, Food & Beverage, Automotive, Semiconductor, Energy, Life Sciences, and more. With a balanced distribution of company sizes with revenues spanning $100 million to over $30 billion, it offers a wide breadth of manufacturing business perspectives.
About Rockwell Automation
Rockwell Automation, Inc. (NYSE: ROK), is a global leader in industrial automation and digital transformation. We connect the imaginations of people with the potential of technology to expand what is humanly possible, making the world more productive and more sustainable. Headquartered in Milwaukee, Wisconsin, Rockwell Automation employs approximately 29,000 problem solvers dedicated to our customers in more than 100 countries. To learn more about how we are bringing the Connected Enterprise to life across industrial enterprises, visit www.rockwellautomation.com.
About the Rockwell Automation PartnerNetwork™
Rockwell Automation believes we're better together—and we do our part by delivering an expansive, global partner ecosystem of market-leading technology, superior support and services, and an integrated and streamlined approach to business. Succeed on an international scale by utilizing our network's breadth of innovative technologies and services that no single vendor can provide alone. To learn more about how the PartnerNetwork is helping to deliver the value of The Connected Enterprise, visit PartnerNetwork Program.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240326554889/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Curing the Incurable with ‘Biological Age Zero’ Cells: Clonell™ Launches the Ultimate Regenerative Medicine Platform5.1.2026 14:00:00 CET | Press release
Fundamental Cure for Intractable and Incurable Diseases using ‘Biological Age Zero’ Cells Derived from Patient’s Own Cells via SCNT TechnologyWorld's First Therapy Platform Simultaneously Solving Immune Rejection and Inheritance of Cellular Aging—The Major Hurdles of Existing Stem Cell TherapiesDrastically Improving Treatment Accessibility through the New Paradigm, ‘Patient-Initiated Clinical Trial™’, which Overcomes Existing Clinical Limitations Clonell Therapeutics, Inc., a leading biotechnology company dedicated to curing intractable and incurable diseases, announced today the official launch of the world's first 'Patient-Specific Embryonic Stem Cell (Somatic Cell Nuclear Transfer-derived Embryonic Stem Cell, hereinafter SCNT-ESC)' therapy platform based on Somatic Cell Nuclear Transfer (SCNT) technology. Concurrently, the company has initiated its innovative 'Patient-Initiated Clinical Trial™' to apply this breakthrough technology directly to patients. This platform launch is evalu
HELUS Pharma Propels Therapeutic Innovation in Mental Health and Commences Trading on Nasdaq5.1.2026 13:30:00 CET | Press release
Helus Pharma builds on the strong foundation originally created as Cybin Inc., reflecting the Company’s ongoing transformation to a commercial stage pharmaceutical company Helus Pharma commences trading on Nasdaq Global Market (“Nasdaq”) and on Cboe Canada under ticker symbol: HELP Helus Pharma continues to progress its portfolio of novel serotonergic agonists (“NSAs”), with the goal of developing treatments designed to redefine mental health care, including HLP004 for the treatment of generalized anxiety disorder, with Phase 2 topline data readout expected in Q1 2026 Preparations in progress for the commercialization of HLP003, Helus Pharma’s NSA in Phase 3 clinical development, which has been granted Breakthrough Therapy Designation by the FDA for the adjunctive treatment of major depressive disorder This news release constitutes a “designated news release” for the purpose of the Company’s prospectus supplement dated December 30, 2025, to it short form base shelf prospectus dated Sep
Incyte Announces Positive Topline Results from Pivotal Study of Tafasitamab (Monjuvi®/Minjuvi®) as a First-line Treatment for Diffuse Large B-Cell Lymphoma5.1.2026 13:30:00 CET | Press release
- Phase 3 frontMIND trial evaluating the efficacy and safety of tafasitamab (Monjuvi®/Minjuvi®) and lenalidomide in addition to R-CHOP met its primary endpoint of progression-free survival (PFS) - Based on these results, Incyte plans to file a supplemental Biologics License Application (sBLA) for tafasitamab and lenalidomide in addition to R-CHOP in first-line diffuse large B-cell lymphoma (DLBCL) in the first half of 2026 Incyte (Nasdaq:INCY) today announced positive topline results from the pivotal Phase 3 frontMIND trial evaluating the efficacy and safety of tafasitamab (Monjuvi®/Minjuvi®), a humanized Fc-modified cytolytic CD19 targeting monoclonal antibody, and lenalidomide in addition to R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone) compared to R-CHOP alone as a first-line treatment for adults with newly diagnosed diffuse large B-cell lymphoma (DLBCL) with an International Prognostic Index (IPI) score of three to five (3-5) for patients >60 years o
SBC Medical Accelerates Global Expansion with Strategic Investment and Alliance witha Leading U.S. MedSpa Platform OrangeTwist as Part of Broader Growth Strategy5.1.2026 13:00:00 CET | Press release
SBC Medical Group Holdings Incorporated (Nasdaq: SBC) (“SBC Medical” or the “Company”), a global provider of comprehensive consulting and management services to medical corporations and their clinics, today announced the completion of a strategic minority equity investment and the establishment of a structured collaboration framework with OrangeTwist, a leading U.S.-based MedSpa chain, alongside its longstanding institutional shareholders, Hildred Capital and Athyrium Capital. This transaction marks SBC Medical’s formal entry into the United States—a key global market for medical aesthetics—and represents a major milestone in the Company’s broader global expansion strategy. For more details, click here. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251210926005/en/ OrangeTwist Supporting 258 affiliated clinics worldwide and managing more than six million patient visits annually, SBC Medical has built one of the largest and
Takeda and Protagonist Announce Submission of New Drug Application (NDA) for Rusfertide for Treatment of Polycythemia Vera (PV)5.1.2026 13:00:00 CET | Press release
Rusfertide Is a First-in-Class Investigational Hepcidin Mimetic That Targets Red Blood Cell Overproduction (Erythrocytosis) in Polycythemia Vera NDA Includes 52-Week Data from Phase 3 VERIFY Study, Which Met the Primary and All Four Key Secondary Endpoints, Showing Rusfertide Provided Durable and Sustained Hematocrit Control and Improved Pre-Specified Patient Reported Outcome Measures Data Underscore the Potential to Shift the Treatment Paradigm for PV Patients to Reduce the Burden of Frequent Phlebotomies and Meaningfully Improve Hematocrit Control Takeda (TSE:4502/NYSE:TAK) and Protagonist Therapeutics (Nasdaq: PTGX) (“Protagonist”) announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) seeking approval of rusfertide for the treatment of adults with polycythemia vera (PV). Rusfertide is an investigational first-in-class subcutaneously administered hepcidin mimetic peptide designed to regulate iron homeostasis and red blood cell product
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom